Precise Quantification of Fever in Childhood Bacterial Meningitis

1992 ◽  
Vol 31 (4) ◽  
pp. 221-227 ◽  
Author(s):  
Marja Anttila ◽  
Jaakko-Juhani Himberg ◽  
Heikki Peltola

Precise quantity of fever was determined in 191 cases of childhood bacterial meningitis by calculating the areas between the line indicating 37.8°C or 39.5°C temperature and the line connecting all individual temperature values. Temperature measurements were performed rectally one to four times a day throughout the hospitalization. The obtained areas under the curves (AUC), expressed as degree-hours, proved to be a sensitive index for delineating each individual fever pattern and reflected the magnitude of fever more precisely than the traditional fever curves. Children under five had significantly (p <0.05) greater AUC than those at five to 15 years; similarly, patients with Haemophilus influenzae meningitis showed greater AUC (i.e., had more fever) than those with meningococcal disease ( p <0.05). The overall rates of secondary (14%), persistent (16%), and prolonged fever (8%) were virtually identical to previous reports; no drug fever was reported in this study. In cases with prolonged fever, a significantly higher rate (40%) of neurological complications was found compared to those who became afebrile earlier. This method is potentially utilizable in other diseases and conditions where precise measurement of fever is of clinical or scientific relevance.

1990 ◽  
Vol 161 (6) ◽  
pp. 1210-1215 ◽  
Author(s):  
H. A. Bijlmer ◽  
L. van Alphen ◽  
B. M. Greenwood ◽  
J. Brown ◽  
G. Schneider ◽  
...  

2020 ◽  
Author(s):  
Saber Heidari ◽  
Manoochehr Karami ◽  
Seyed Mohsen Zahraei ◽  
Iraj Sedighi ◽  
Fatemeh Azimian Zavareh

Abstract Background Ensuring the effectiveness of the Haemophilus influenza type b (DTwP-Hib-HepB) vaccine in reducing meningitis is an essential approach in evaluating the effectiveness of the vaccine. The study aimed to address the epidemiology of meningitis following pentavalent vaccination in Iran. Methods In this descriptive study, data from meningitis patients from 21st March 2011 to 21st July 2018 were extracted from the National Notifiable Diseases Surveillance System. This information was divided into two equal periods before the pentavalent vaccine introduction (21st March 2011 to 17th November 2014) and after the introduction (18th November 2014 to 21st July 2018). Descriptive statistics indices, including frequency, percentages, tables, and graphs, were used to describe the study population. Results The number of patients in the study period was 53,174 cases. More than 55% of patients were under five years old. Males (63.34%) were more than females (36.06%). From the clinical point of view, 90.56% had a fever, 57.87% vomited, 53.78% had a headache, and 26.27% had neck stiffness. The death rate was reduced to 2.1%; also, the proportion of confirmed cases caused by Haemophilus influenzae type b was 6.7% before the pentavalent vaccine introduction. The corresponding value following vaccine introduction equals to 3.6%. The proportion of children under five has decreased from 4.4–1.9%. This value indicates a 46.2% decrease in the meningitis of all ages and a 57% decrease in children under five due to Haemophilus influenzae vaccination. Conclusions The results of the study indicate the effectiveness of the vaccine due to changes in meningitis caused by Haemophilus influenzae type b after vaccination compared with no vaccination. Therefore, it is advisable to continue the full immunization coverage with the pentavalent vaccine.


1999 ◽  
Vol 94 (4) ◽  
pp. 477-478
Author(s):  
Isis Tamargo ◽  
Gilda Toraño ◽  
Oxandra Rodriguez ◽  
Miriam Perez ◽  
Alina Llop

2021 ◽  
Vol 10 (Supplement_1) ◽  
pp. S15-S15
Author(s):  
X León-Lara ◽  
I Medina-Vera ◽  
E Arias de la Garza ◽  
M Macías-Parra

Abstract Background Bacterial meningitis (BM) remains a significant global health problem in pediatric care, with substantial morbidity and mortality. The epidemiology of BM has changed over the last 20 years. The ongoing introduction of conjugate vaccines for the most common meningeal pathogens has reduced the global incidence. However, there is limited epidemiologic and microbiologic data of BM in children before and after the widespread use of these vaccines in Mexico. Methods We conducted a retrospective, observational, analytical study. Pediatric patients (from 1 month to 18 years of age) presenting with BM and hospitalized at the Instituto Nacional de Pediatria in Mexico City, from 1990 to 2018, were included. Meningitis from invasive procedures or complicated head trauma were excluded. BM was classified according to the World Health Organization (WHO) criteria. The cases were analyzed in three periods: period A (1990–1999), period B (2000–2008), and period C (2009–2018). Period A corresponds to the time before the conjugate Haemophilus influenzae type b (Hib vaccine) was introduced in Mexico, while periods B and C correspond to the time after the Hib vaccine was routinely applied. Periods A and B correspond to the period before the pneumococcal conjugate vaccine (PCV7) was administrated in Mexico, while period C is after PCV7 and PCV13 were routinely administrated. The proportion of cases between periods was compared with Chi-square or Fisher exact test; P &lt; 0.05 was considered significant. Binomial logistic regression analysis was used to determine the association between potential risk factors and death due to BM. Results A total of 226 cases with BM were included, 180 (79.6%) confirmed cases, and 46 (20.4%) probable cases. The median age at diagnosis was 10 months. There were 126 (55.8%) cases in Period A, 62 (27.4%) cases in Period B, and 38 (16.8%) cases in Period C, with a statistically significant reduction between periods (P = 0.0001). Hib was the most commonly isolated pathogen, found in 38 (50%) cases. However, its proportion declined significantly after the introduction of the Hib conjugate vaccine (P &lt; 0.0001). S. pneumoniae followed as the second most commonly isolated bacterial pathogen. There was a significant reduction in neurological complications after the Hib conjugate vaccine (P = 0.003) and the S. pneumoniae conjugate vaccine (P = 0. 05) were introduced. Independent risk factors associated with mortality were coma (OR 15, P = 0. 0001), intracerebral bleeding (OR 3.5, P = 0.046), and pneumococcal meningitis (OR 9.4, P = 0. 002). Conclusions BM remains a cause of morbidity and mortality in pediatric patients in this hospital, with a dramatic change in the epidemiology since the introduction of the Hib conjugate vaccine to the national immunization schedule. Routine use of childhood conjugate vaccines against the most frequent etiological agents reduced the number of cases globally, mainly those caused by Hib. Additionally, conjugate vaccines reduced neurological complications and sequelae caused by this disease.


2017 ◽  
Vol 07 (04) ◽  
pp. 300-308
Author(s):  
E. Moyen ◽  
S. S. J. Dinga Boudjoumba ◽  
J. Kambourou ◽  
A. P. G. Oko ◽  
A. R. Okoko ◽  
...  

Author(s):  
Mercedes Macias Parra ◽  
Isabel Medina-Vera ◽  
Eduardo Arias De la Garza ◽  
Miguel A. Rodriguez Weber ◽  
Ximena León-Lara

Abstract Objective The study aimed to compare the epidemiology of bacterial meningitis (BM) before and after vaccination, and identify possible risk factors associated with mortality. Methods The medical and microbiologic records of children (1 month–18 years) with a discharge diagnosis of BM in a third level children's hospital in Mexico from 1990 to 2018 were reviewed. The epidemiology, pathogens, and outcomes were compared before and after introducing Haemophilus influenzae type b (Hib) and pneumococcal conjugate vaccines to the Mexican immunization schedule. Risk factors associated with mortality were determined. Results In the 28-year period, 226 cases with BM were included 55.8% (1990–1999), 27.4% (2000–2008), and 16.8% (2009–2018) (p = 0.0001). The most frequent pathogen was Hib, documented in 39% of cases. There was a reduction in neurological complications after introducing the Hib conjugate vaccine (59 vs. 39%; p = 0.003) and sequelae after the Streptococcus pneumoniae conjugate vaccine (43 vs. 35%; p = 0.05). Independent risk factors associated with mortality were coma (odds ratio [OR]: 15 [2.9–78]), intracerebral bleeding (OR: 3.5 [1.4–12]), and pneumococcal meningitis (OR: 9.4 [2.2–39]). Conclusion Since the introduction of Hib and pneumococcal conjugate vaccines to the national immunization schedule, there was a reduction in BM cases, mainly associated with the Hib vaccine, with the consequent reduction of neurological complications and sequelae.


Sign in / Sign up

Export Citation Format

Share Document